Optibrium, a developer of software and AI solutions for drug discovery, has acquired BioPharmics in a view to expand its 3D drug design and modelling offering.
Instead of continuing to rely on trial-and-error testing, pharmaceutical scientists are increasingly turning to computer software to create better treatments.